EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Bondeson, 2015, Catalytic in vivo protein knockdown by small-molecule PROTACs, Nat. Chem. Biol., 11, 611, 10.1038/nchembio.1858

Buckley, 2012, Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction, J. Am. Chem. Soc., 134, 4465, 10.1021/ja209924v

Dimou, 2017, Epigenetics during EMT in lung cancer: EZH2 as a potential therapeutic target, Cancer Treat. Res. Commun., 12, 40, 10.1016/j.ctarc.2017.06.003

Garapaty-Rao, 2013, Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth, Chem. Biol., 20, 1329, 10.1016/j.chembiol.2013.09.013

He, 2017, The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex, Nat. Chem. Biol., 13, 389, 10.1038/nchembio.2306

Huang, 2017, Discovery of first-in-class, potent, and orally bioavailable embryonic ectoderm development (EED) inhibitor with robust anticancer efficacy, J. Med. Chem., 60, 2215, 10.1021/acs.jmedchem.6b01576

Italiano, 2018, Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study, Lancet Oncol., 19, 649, 10.1016/S1470-2045(18)30145-1

Kim, 2016, Targeting EZH2 in cancer, Nat. Med., 22, 128, 10.1038/nm.4036

Knutson, 2014, Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma, Mol. Cancer Ther., 13, 842, 10.1158/1535-7163.MCT-13-0773

Lai, 2017, Induced protein degradation: an emerging drug discovery paradigm, Nat. Rev. Drug Discov., 16, 101, 10.1038/nrd.2016.211

Lawrence, 2016, Non-canonical EZH2 transcriptionally activates RelB in triple negative breast cancer, PLoS One, 11, e0165005, 10.1371/journal.pone.0165005

Lee, 2011, Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers, Mol. Cell, 43, 798, 10.1016/j.molcel.2011.08.011

Leeb, 2010, Polycomb complexes act redundantly to repress genomic repeats and genes, Genes Dev., 24, 265, 10.1101/gad.544410

McCabe, 2012, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations, Nature, 492, 108, 10.1038/nature11606

Morin, 2010, Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin, Nat. Genet., 42, 181, 10.1038/ng.518

Qi, 2017, An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED, Nat. Chem. Biol., 13, 381, 10.1038/nchembio.2304

Seki, 2018, Optimized RNP transfection for highly efficient CRI SPR/Cas9-mediated gene knockout in primary T cells, J. Exp. Med., 215, 985, 10.1084/jem.20171626

Smith, 2019, Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase, Nat. Commun., 10, 131, 10.1038/s41467-018-08027-7

Xu, 2012, EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent, Science, 338, 1465, 10.1126/science.1227604

Xu, 2015, Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions, Mol. Cell, 57, 304, 10.1016/j.molcel.2014.12.009